BofA warns Fed risks policy mistake with early rate cuts
On Friday, H.C. Wainwright analyst Douglas Tsao increased the price target on argenx SE (NASDAQ:ARGX) shares to $720 from $717, while maintaining a "Buy" rating for the stock. Currently trading at $624.70, the company has demonstrated impressive strength with a 57% return over the past year. According to InvestingPro data, analyst targets range from $523 to $872, reflecting diverse market expectations. The adjustment follows argenx’s management discussions about patient free services (PFS) and its potential impact on gross-to-net (GTN) revenue.
Management at argenx SE provided insights into the expected financial dynamics following the introduction of PFS for Vyvgart patients. With an impressive gross profit margin of 89.91% and strong financial health score rated as "GREAT" by InvestingPro, the company appears well-positioned to manage this transition. They noted that although there will be a transition of self-administration patients from Medicare Part B to Part D, where the value-based agreement with payers would not be applicable, the anticipated increase in patient volumes is likely to balance the rise in GTN. This is significant as approximately half of the Vyvgart patient base is covered by Medicare. Additionally, the company is preparing for the Medicare Part D redesign, which will introduce manufacturer obligations for catastrophic coverage.
The company officials also mentioned that they expect the usual seasonal patterns to influence the first quarter’s performance. With remarkable revenue growth of 77.52% over the last twelve months, they forecasted a higher single-digit quarter-over-quarter growth for the first quarter, which was 6% in the same quarter of the previous year. This prediction is based on the company’s historical data and market trends. Discover more detailed growth metrics and 14 additional key insights with InvestingPro’s comprehensive research report.
Looking ahead, argenx SE is planning to release Vyvgart in an autoinjector format by 2027. This move is aimed at expanding administration options for patients and enhancing patient accessibility to the treatment. The introduction of the autoinjector is part of the company’s long-term strategy to improve patient experience and potentially drive further growth.
In response to these updates, H.C. Wainwright revised their sales estimates for argenx, which resulted in the slight increase in the price target for the company’s stock. The new price target of $720 reflects the firm’s confidence in argenx’s strategy and its potential to generate increased revenue through the upcoming changes in product offerings and market adaptations.
In other recent news, argenx SE has reported impressive fourth-quarter 2024 financial results, with revenue from Vyvgart reaching $737 million, marking a 29% increase quarter-over-quarter. Analysts from TD Cowen and Jefferies noted that these results significantly surpassed their expectations, leading them to raise their price targets to $761 and $772, respectively. JMP Securities also adjusted its price target slightly to $701, highlighting the strong performance of the VYVGART franchise and its anticipated future growth. Truist Securities expressed confidence in argenx’s financial trajectory, raising their price target to $700 and emphasizing the company’s potential to exceed its Vision 2030 goals.
Furthermore, H.C. Wainwright raised their price target to $717, citing confidence in the company’s lead asset, efgartigimod, and its broad pipeline. Analysts have noted the potential regulatory milestones and clinical advancements expected in 2025, which could further bolster argenx’s market position. The company concluded the year with a cash reserve of approximately $3.5 billion and has provided guidance for 2025 operating expenses to be around $2.5 billion. Argenx ’s strategic focus on advancing its product pipeline and achieving profitability by 2025 has been well-received by analysts, who maintain a positive outlook on the company’s growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.